Enovis (NYSE:ENOV – Get Free Report) and P3 Health Partners (NASDAQ:PIII – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Risk and Volatility
Enovis has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for Enovis and P3 Health Partners, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 2 | 0 | 7 | 1 | 2.70 |
| P3 Health Partners | 1 | 2 | 1 | 0 | 2.00 |
Earnings and Valuation
This table compares Enovis and P3 Health Partners”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $2.25 billion | 0.64 | -$1.18 billion | ($19.88) | -1.27 |
| P3 Health Partners | $1.46 billion | 0.05 | -$147.95 million | ($38.60) | -0.26 |
P3 Health Partners has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enovis and P3 Health Partners’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enovis | -49.92% | 10.32% | 4.57% |
| P3 Health Partners | -8.57% | N/A | -19.99% |
Insider and Institutional Ownership
98.5% of Enovis shares are held by institutional investors. Comparatively, 7.7% of P3 Health Partners shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 10.9% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Enovis beats P3 Health Partners on 10 of the 15 factors compared between the two stocks.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
